Hyperhomocysteinemia in Patients with Parkinson’s Disease and Relationship to Vitamin B Level

Background: Plasma homocysteine (Hcy) levels are increased in patients with Parkinson’s disease (PD) undergoing levodopa treatment. We measured the Hcy levels in PD patients and assessed the relationship between Hcy level and features of PD, cognitive function and vitamin B status. Methods: Concentr...

Full description

Bibliographic Details
Main Authors: Hae-Won Shin, Young Ho Sohn
Format: Article
Language:English
Published: Korean Movement Disorders Society 2009-05-01
Series:Journal of Movement Disorders
Subjects:
Online Access:http://e-jmd.org/upload/jmd-2-1-33-8.pdf
id doaj-16aee3e4fb4e42f2a6a4e9af3021d623
record_format Article
spelling doaj-16aee3e4fb4e42f2a6a4e9af3021d6232020-11-25T00:01:36ZengKorean Movement Disorders SocietyJournal of Movement Disorders2005-940X2093-49392009-05-0121333610.14802/jmd.0900895Hyperhomocysteinemia in Patients with Parkinson’s Disease and Relationship to Vitamin B LevelHae-Won ShinYoung Ho SohnBackground: Plasma homocysteine (Hcy) levels are increased in patients with Parkinson’s disease (PD) undergoing levodopa treatment. We measured the Hcy levels in PD patients and assessed the relationship between Hcy level and features of PD, cognitive function and vitamin B status. Methods: Concentrations of Hcy, vitamin B12 and folate were measured in 33 PD patients and 41 normal control individuals. Mini-mental Status Examination (MMSE) was assessed in all subjects. In PD patients, Hoehn & Yahr stage and Unified Parkinson Disease Rating Scale (UPDRS) motor scores were also examined. Results: Plasma Hcy levels were lower in PD patients than in control individuals. Hcy level was inversely correlated with vitamin B12 and folate levels in the PD group but not in control individuals. Age, symptom duration, UPDRS motor scores, MMSE score, levodopa dose and duration of treatment did not differ between patients with Hcy >14 μmol/L and those with Hcy <14 μmol/L. Conclusions: Plasma Hcy levels were increased in PD patients with levodopa treatment and were related to vitamin B level. These results indicate that vitamin supplementation may be beneficial in levodopa-treated PD patients, although hyperhomocysteinemia did not affect the motor and cognitive status of PD patients.http://e-jmd.org/upload/jmd-2-1-33-8.pdfParkinson’s diseaseHomocysteineVitamin B
collection DOAJ
language English
format Article
sources DOAJ
author Hae-Won Shin
Young Ho Sohn
spellingShingle Hae-Won Shin
Young Ho Sohn
Hyperhomocysteinemia in Patients with Parkinson’s Disease and Relationship to Vitamin B Level
Journal of Movement Disorders
Parkinson’s disease
Homocysteine
Vitamin B
author_facet Hae-Won Shin
Young Ho Sohn
author_sort Hae-Won Shin
title Hyperhomocysteinemia in Patients with Parkinson’s Disease and Relationship to Vitamin B Level
title_short Hyperhomocysteinemia in Patients with Parkinson’s Disease and Relationship to Vitamin B Level
title_full Hyperhomocysteinemia in Patients with Parkinson’s Disease and Relationship to Vitamin B Level
title_fullStr Hyperhomocysteinemia in Patients with Parkinson’s Disease and Relationship to Vitamin B Level
title_full_unstemmed Hyperhomocysteinemia in Patients with Parkinson’s Disease and Relationship to Vitamin B Level
title_sort hyperhomocysteinemia in patients with parkinson’s disease and relationship to vitamin b level
publisher Korean Movement Disorders Society
series Journal of Movement Disorders
issn 2005-940X
2093-4939
publishDate 2009-05-01
description Background: Plasma homocysteine (Hcy) levels are increased in patients with Parkinson’s disease (PD) undergoing levodopa treatment. We measured the Hcy levels in PD patients and assessed the relationship between Hcy level and features of PD, cognitive function and vitamin B status. Methods: Concentrations of Hcy, vitamin B12 and folate were measured in 33 PD patients and 41 normal control individuals. Mini-mental Status Examination (MMSE) was assessed in all subjects. In PD patients, Hoehn & Yahr stage and Unified Parkinson Disease Rating Scale (UPDRS) motor scores were also examined. Results: Plasma Hcy levels were lower in PD patients than in control individuals. Hcy level was inversely correlated with vitamin B12 and folate levels in the PD group but not in control individuals. Age, symptom duration, UPDRS motor scores, MMSE score, levodopa dose and duration of treatment did not differ between patients with Hcy >14 μmol/L and those with Hcy <14 μmol/L. Conclusions: Plasma Hcy levels were increased in PD patients with levodopa treatment and were related to vitamin B level. These results indicate that vitamin supplementation may be beneficial in levodopa-treated PD patients, although hyperhomocysteinemia did not affect the motor and cognitive status of PD patients.
topic Parkinson’s disease
Homocysteine
Vitamin B
url http://e-jmd.org/upload/jmd-2-1-33-8.pdf
work_keys_str_mv AT haewonshin hyperhomocysteinemiainpatientswithparkinsonsdiseaseandrelationshiptovitaminblevel
AT younghosohn hyperhomocysteinemiainpatientswithparkinsonsdiseaseandrelationshiptovitaminblevel
_version_ 1725441177547702272